Figure 7.

Flow cytometry data for determination of tumor-infiltrating T cells for possible synergistic effects between anti-PD1 and ¹⁷⁷Lu-h8C3 antibody. Groups of four tumor-bearing mice (three treatments of anti-PD1), single injection of ¹⁷⁷Lu, three treatments of anti-PD1 followed by one treatment of ¹⁷⁷Lu-8hC3, and one treatment of ¹⁷⁷Lu-h8C3) or six mice (control) were treated and sacrificed on day 20. Tumors were harvested and analyzed by (a) comparing % of CD8+ cells among CD45+ cells, (b) comparing % of CD4+ cells among CD45+ cells, and (c) comparing % of Treg+ cells among CD45+/CD4+/foxP3+ cells for each cohort. Each data point represents one animal in each group. No significance was found in any treatment group relative to control.